A Study To Investigate Ataciguat For Slowing The Progression Of Moderate Calcific Aortic Valve Stenosis

Overview

About this study

The purpose of this study is to evaluate if ataciguat slows the progression of moderate calcific aortic valve stenosis in adults.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Key Inclusion Criteria:

1. Adult male or female at least 50 years of age
2. Has moderate CAVS as defined by:

1. An AVA of ≥1 cm2 to ≤1.50 cm2
2. An AVC score between ≥600 to 1200 Agatston units (AU) for women and between ≥600 to 2000 AU for men
3. Has a left ventricular ejection fraction (EF) of ≥45% at the time of Screening as determined by the echocardiography Core Laboratory
4. Can perform Cardiopulmonary Exercise Testing (CPET)

Key Exclusion Criteria:

1. Has had a prior aortic valve replacement, repair, surgery, or intervention
2. Has moderate, moderate-to-severe, or severe (Grade 2 or higher) mitral stenosis, mitral regurgitation, and/or aortic regurgitation
3. Has known congenital aortic valve disease including bicuspid aortic valve
4. New York Heart Association (NYHA) Class III or Class IV
5. Has heart failure such as cardiomyopathy, congenital heart disease, myocarditis
6. Has coronary artery disease or anticipating coronary stenting surgery
7. Abnormal electrocardiogram (ECG) results or long-standing persistent or permanent atrial fibrillation

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Ratnasari Padang

Open for enrollment

Contact information:

Structural Heart Disease Research Coordinators

(507) 255-6133

More information

Publications

Publications are currently not available
.
CLS-20597205

Mayo Clinic Footer